1. Home
  2. CAC vs OMER Comparison

CAC vs OMER Comparison

Compare CAC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camden National Corporation

CAC

Camden National Corporation

HOLD

Current Price

$45.29

Market Cap

680.5M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.18

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAC
OMER
Founded
1875
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
680.5M
628.9M
IPO Year
1997
2009

Fundamental Metrics

Financial Performance
Metric
CAC
OMER
Price
$45.29
$10.18
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$47.33
$27.50
AVG Volume (30 Days)
72.7K
1.7M
Earning Date
01-27-2026
11-13-2025
Dividend Yield
3.72%
N/A
EPS Growth
9.13
N/A
EPS
3.49
N/A
Revenue
$215,172,000.00
N/A
Revenue This Year
$44.50
N/A
Revenue Next Year
$7.03
N/A
P/E Ratio
$12.94
N/A
Revenue Growth
27.50
N/A
52 Week Low
$34.53
$2.95
52 Week High
$46.99
$13.60

Technical Indicators

Market Signals
Indicator
CAC
OMER
Relative Strength Index (RSI) 76.69 59.20
Support Level $41.38 $9.31
Resistance Level $41.60 $11.71
Average True Range (ATR) 1.14 0.67
MACD 0.39 -0.01
Stochastic Oscillator 97.56 51.11

Price Performance

Historical Comparison
CAC
OMER

About CAC Camden National Corporation

Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: